oricar-017
oricell therapeutics
['car-t', 'polaris']
#qmportfolio oricell therapeutics reported positive results from phase i polaris study that evaluates oricar-017 in patients with rrmm at asco annual meeting, marking the first time that clinical data on car-t therapy targeting gprc5d have been reported in china. 
Founded in 2006, Qiming is a leading China VC firm with over US$6.2 billion assets under management. We invest in the TMT and healthcare industries.